Voya Investment Management LLC Sells 24,563 Shares of Lantheus Holdings, Inc. $LNTH

Voya Investment Management LLC lessened its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 34.3% during the third quarter, HoldingsChannel.com reports. The firm owned 46,956 shares of the medical equipment provider’s stock after selling 24,563 shares during the quarter. Voya Investment Management LLC’s holdings in Lantheus were worth $2,408,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Elevation Point Wealth Partners LLC acquired a new stake in shares of Lantheus in the second quarter valued at approximately $26,000. Osterweis Capital Management Inc. bought a new position in Lantheus during the 2nd quarter worth $36,000. Quarry LP increased its stake in Lantheus by 2,350.0% during the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock worth $48,000 after acquiring an additional 470 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Lantheus by 190.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after acquiring an additional 698 shares in the last quarter. Finally, EMC Capital Management acquired a new position in Lantheus in the 2nd quarter valued at $93,000. 99.06% of the stock is owned by institutional investors.

Lantheus Trading Up 0.0%

Shares of Lantheus stock opened at $66.71 on Friday. The firm’s 50 day moving average is $58.96 and its 200 day moving average is $62.23. The firm has a market capitalization of $4.42 billion, a PE ratio of 28.03 and a beta of -0.10. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $111.29. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. The firm had revenue of $92.51 million for the quarter. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. Equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LNTH has been the topic of several analyst reports. The Goldman Sachs Group set a $77.00 target price on Lantheus and gave the stock a “neutral” rating in a report on Wednesday, October 8th. Mizuho increased their price objective on shares of Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. B. Riley decreased their target price on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday, September 16th. Weiss Ratings cut shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday, October 25th. Finally, Truist Financial increased their price target on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $78.00.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.